A unique window of opportunity for practical reform of cancer clinical trials.
Dan T VoglVicki SalléeMaria C HendricksColleen Redlinger TaberyMeghan L BlairErica DahlmeierEmma A MeagherRoger B CohenRobert H VonderheidePublished in: Cancer (2021)
With rapid modifications in cancer clinical trial operations necessitated by the global pandemic over the last year, there is now an unprecedented opportunity to reform clinical research permanently and solidify innovative practices that have clearly been effective. On the basis of the authors' experience and recommendations from other institutions, a set of specific proposals for clinical trial reform are identified that can be implemented immediately by sponsors, regulators, and study sites. Improvements in clinical trial processes should include increased leverage of technology to facilitate remote trial activity and electronic documents, more efficient and effective communication of adverse event information, and better study design to optimize inclusion criteria, required research procedures, and data collection. The authors suggest that such reform will preserve patient safety and study integrity, address unnecessary and inefficient pre-pandemic constraints, improve access to clinical trials for patients, and speed improvements in cancer care.
Keyphrases
- clinical trial
- phase ii
- patient safety
- phase iii
- study protocol
- open label
- papillary thyroid
- coronavirus disease
- health insurance
- sars cov
- double blind
- end stage renal disease
- healthcare
- chronic kidney disease
- primary care
- ejection fraction
- randomized controlled trial
- big data
- health information
- young adults
- electronic health record
- patient reported outcomes
- patient reported
- loop mediated isothermal amplification